Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma. (Q53482041)

14 May 2018

title

Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma. (English)

1 reference

14 May 2018

0 references

Hui Wang

1

1 reference

14 May 2018

Ying Liu

2

1 reference

14 May 2018

Xiu Wang

3

1 reference

14 May 2018

Donghui Liu

4

1 reference

14 May 2018

Zhiqiang Sun

5

1 reference

14 May 2018

Chun Wang

6

1 reference

14 May 2018

Gang Jin

7

1 reference

14 May 2018

Beiguang Zhang

8

1 reference

14 May 2018

Shilong Yu

9

1 reference

14 May 2018

language of work or name

English

0 references

publication date

29 May 2015

1 reference

14 May 2018

published in

Cancer

1 reference

14 May 2018

volume

121

1 reference

14 May 2018

issue

17

1 reference

14 May 2018

page(s)

2917-2925

1 reference

14 May 2018

Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Cancer: a Systems Biology disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Acute promyelocytic leukemia: what is the new standard of care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Effect of arsenic trioxide on human hepatocarcinoma in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

ABCG2: determining its relevance in clinical drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Identification of local and circulating cancer stem cells in human liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Novel therapeutic strategies for targeting liver cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Inhibition by arsenic trioxide of human hepatoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide treatment of rabbit liver VX-2 carcinoma via hepatic arterial cannulation-induced apoptosis and decreased levels of survivin in the tumor tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intraarterial versus intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

7 January 2021

inferred from DOI database lookup

Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

7 January 2021

inferred from DOI database lookup

Report of the 15th follow-up survey of primary liver cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/CNCR.29456

1 reference

14 May 2018

release_ef66i4xf7bhwhh7csfui7qfu7y

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ef66i4xf7bhwhh7csfui7qfu7y

24 November 2022

mapped directly with Wikidata item

PubMed ID

26033499

1 reference

14 May 2018